Clinical significance of post-progression survival in lung cancer
Author:
Affiliation:
1. Division of Respiratory Medicine; Gunma Prefectural Cancer Center; Ota Japan
2. Department of Oncology Clinical Development; Gunma University Graduate School of Medicine; Maebashi Japan
Publisher
Wiley
Subject
Pulmonary and Respiratory Medicine,Oncology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/1759-7714.12463/fullpdf
Reference51 articles.
1. Kasper D Fauci A Hauser S Longo D Jameson J Loscalzo J 19th edn McGraw-Hill Education New York 2015
2. Cancer statistics, 2012;Siegel;CA Cancer J Clin,2012
3. Detecting an overall survival benefit that is derived from progression-free survival;Broglio;J Natl Cancer Inst,2009
4. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?;Soria;Ann Oncol,2010
5. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil;Reck;J Clin Oncol,2009
Cited by 49 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Olanzapine suppresses mPFC activity-norepinephrine releasing to alleviate CLOCK-enhanced cancer stemness under chronic stress;Cell Communication and Signaling;2024-07-25
2. Peritumoural MRI radiomics signature of brain metastases can predict epidermal growth factor receptor mutation status in lung adenocarcinoma;Clinical Radiology;2024-02
3. First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis;Strahlentherapie und Onkologie;2023-11-17
4. Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study;Clinical Cancer Research;2023-05-26
5. The prognostic utility of dynamic risk stratification at disease progression in patients with multiple myeloma;Hematology;2023-02-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3